PROVIDENCE – New research from Rhode Island Hospital found that obesity and Type 2 Diabetes Mellitus (T2DM) can contribute to mild neurodegeneration with features common with Alzheimer's disease (AD) – the first study to show that obesity can cause neurodegeneration. The study appeared in the Journal of Alzheimer's Disease Volume 15:1 (September 2008) .
In a study on animal models, lead researcher Suzanne de la Monte, MD, MPH, of Rhode Island Hospital, utilized chronic high fat diets to cause a two-fold increase in mean body weight. In these animal models, there was a marginally reduced mean brain weight and a significantly reduced mean brain weight/body weight ratio, providing evidence that obesity with T2DM is sufficient to cause mild global atrophy in the brain.
De la Monte says, "In essence, the brain shrinks and several biochemical and molecular abnormalities found in patients with AD, including brain insulin resistance, develop with chronic obesity and T2DM. However, the extent of the abnormalities in no way matches AD." Researchers note that the neuropathological abnormalities were mild and the associated brain insulin resistance could serve as a co-factor in the development and progression of AD.
Overall, the study found that that the effects of obesity and T2DM can essentially aggravate or contribute to the severity or progression of AD, but cannot be the sole cause of the condition. The findings suggest that strategies to reduce obesity and prevent or control T2DM could modify the clinical course of mild cognitive impairment and AD.
De la Monte also notes, "We don't know yet if these effects of T2DM/obesity are reversible with weight loss. However, we're fairly sure that the abnormalities are related to the T2DM that accompanies obesity and not just increased weight."
The full study is available at www.j-alz.com.
Founded in 1863, Rhode Island Hospital (www.rhodeislandhospital.org) is a private, not-for-profit hospital and is the largest teaching hospital of the Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Rhode Island Hospital ranks among the country's leading independent hospitals that receive funding from the National Institutes of Health, with research awards of nearly $27 million annually. Many of its physicians are recognized as leaders in their respective fields of cancer, cardiology, diabetes, neurology, orthopedics and minimally invasive surgery. The hospital's pediatrics division, Hasbro Children's Hospital, has pioneered numerous procedures and is at the forefront of fetal surgery, orthopedics and pediatric neurosurgery. Rhode Island Hospital is a founding member of the Lifespan health system.
Moroz, N. et al. (2008). Limited Alzheimer-Type Neurodegeneration in Experimental Obesity and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease. 15(1), 29-44.
The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 4.081 according to Thomson Reuter's 2007 Journal Citation Reports. It is published by IOS Press.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.